Table 1.
Clinical and Pathological Characteristics
| Variable | Summary statistics (percent) |
|---|---|
| Age/years | |
| Mean ± SD | 53.07±14.19 |
| Median (range) | 55 (27-85) |
| Gender | |
| Females | 14 (46.7) |
| Males | 16 (53.3) |
| Site | |
| Anal canal | 12 (40) |
| Colon | 7 (23.33) |
| Rectal | 11 (36.67) |
| Side | |
| Left | 24 (80) |
| Right | 6 (20) |
| Distance from anal verge | |
| Mean ± SD | 18.97±19.35 |
| Median (range) | 10 (2-60) |
| Grade | |
| Grade I | 6 (20) |
| Gradde II | 18 (60) |
| Grade III | 6 (20) |
| T Stage | |
| T2 | 4 (13.33) |
| T3 | 17 (56.67) |
| T4 | 9 (30) |
| N stage | |
| N0 | 9 (30) |
| N1 | 16 (53) |
| N2 | 5 (16.67) |
| M stage | |
| M0 | 19 (63.33) |
| M1 | 11 (36.67) |
| Stage | |
| Stage I | 2 (6.67) |
| Stage II | 7 (23.33) |
| Stage III | 10 (33.33) |
| Stage IV | 11 (36.67) |
| ER degree | |
| Negative | 12 (40.00) |
| Weak | 11 (36.67) |
| Moderate | 5 (16.67) |
| Strong | 2 (6.67) |
| PR degree | |
| Negative | 7 (23.33) |
| Weak | 15 (50) |
| Moderate | 7 (23.33) |
| Strong | 1 (3.33) |
| Chemotherapy lines | |
| 1 | 9 (30) |
| 2 | 6 (20) |
| Variable | Summary statistics (percent) |
| Chemotherapy lines | |
| 3 | 12 (40) |
| 4 | 3 (10) |
| Response | |
| Stationary | 1 (3.33) |
| Progressive | 21 (70) |
| Responsive | 5 (16.67) |
| Lost follow up | 3 (10) |
| PFS/month | |
| Median (range) | 9 (4-53) |
| OS | |
| Median (range) | 27.52 (2.43-58.76) |